

AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-218 (Canceled)

219. (Previously Presented) A polypeptide comprising at least two repetitions of the amino acid sequence defined in SEQ ID NO.:5.

220-223 (Canceled)

224. (New) A polypeptide of from 15 to 64 contiguous amino acids of SEQ ID NO.:1 which inhibits the growth of prostatic adenocarcinoma, wherein said polypeptide comprises SEQ ID NO: 5.

225. (New) A polypeptide consisting of the amino acid sequence defined in SEQ ID NO.:5.

226. (New) A polypeptide as defined in any one of SEQ ID NO.:10, SEQ ID NO.:11, SEQ ID NO.:12, SEQ ID NO.:13, SEQ ID NO.:14, SEQ ID NO.:15, SEQ ID NO.:16, SEQ ID NO.:17, SEQ ID NO.:18, SEQ ID NO.:19, SEQ ID NO.:20, SEQ ID NO.:21, SEQ ID NO.:22, SEQ ID NO.:23, SEQ ID NO.:24, SEQ ID NO.:25, SEQ ID NO.:26, SEQ ID NO.:27, SEQ ID NO.:28, SEQ ID NO.:29, SEQ ID NO.:30, SEQ ID NO.:31, SEQ ID NO.:32, SEQ ID NO.:33, SEQ ID NO.:34, SEQ ID NO.:35, SEQ ID NO.:36, SEQ ID NO.:37, SEQ ID NO.:38, SEQ ID NO.:39, SEQ ID NO.:40, SEQ ID NO.:41, SEQ ID NO.:42, SEQ ID NO.:43, SEQ ID NO.:44, SEQ ID NO.:45, SEQ ID NO.:46, SEQ ID NO.:47, SEQ ID NO.:48, SEQ ID NO.:49, SEQ ID NO.:50, SEQ ID NO.:51, SEQ ID NO.:52, SEQ ID NO.:53, SEQ ID NO.:54, SEQ ID NO.:55, SEQ ID NO.:56, SEQ ID NO.:57, SEQ ID NO.:58, SEQ ID NO.:59, SEQ ID NO.:60, SEQ ID NO.:61, SEQ ID NO.:62, SEQ ID NO.:63, SEQ ID NO.:64, SEQ ID NO.:65, SEQ ID NO.:66, SEQ ID NO.:67, SEQ ID NO.:68, SEQ ID NO.:69, SEQ ID NO.:70, SEQ ID NO.:71,

SEQ ID NO.:72, SEQ ID NO.:73, SEQ ID NO.:74, SEQ ID NO.:75, SEQ ID NO.:76, SEQ ID NO.:77, SEQ ID NO.:78, SEQ ID NO.:79, SEQ ID NO.:80, SEQ ID NO.:81, SEQ ID NO.:82, SEQ ID NO.:83, SEQ ID NO.:84, SEQ ID NO.:85, SEQ ID NO.:86, SEQ ID NO.:87, SEQ ID NO.:88, SEQ ID NO.: 90, SEQ ID NO.: 91 and SEQ ID NO.: 92.

227. (New) A polypeptide which inhibits the growth of prostatic adenocarcinoma, said polypeptide having at least 50% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

228. (New) A polypeptide which inhibits the growth of prostatic adenocarcinoma, said polypeptide having at least 70% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

229. (New) A polypeptide which inhibits the growth of prostatic adenocarcinoma, said polypeptide having at least 90% of its amino acid sequence identical to the amino acid sequence defined in SEQ ID NO.:5.

230. (New) A pharmaceutical composition comprising:

- a) the polypeptide of claim 219; and
- b) a pharmaceutically acceptable carrier.

231. (New) The pharmaceutical composition of claim 230, further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.

232. (New) The pharmaceutical composition of claim 231, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.

233. (New) A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 230.

234. (New) A pharmaceutical composition comprising:
- a) the polypeptide of claim 224; and
 - b) a pharmaceutically acceptable carrier.
235. (New) The pharmaceutical composition of claim 234, further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.
236. (New) The pharmaceutical composition of claim 235, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.
237. (New) A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 234.
238. (New) A pharmaceutical composition comprising:
- a) the polypeptide of claim 225; and
 - b) a pharmaceutically acceptable carrier.
239. (New) The pharmaceutical composition of claim 238, further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.
240. (New) The pharmaceutical composition of claim 239, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.
241. (New) A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 238.
242. (New) A pharmaceutical composition comprising:

- a) the polypeptide of claim 226; and
- b) a pharmaceutically acceptable carrier.

243. (New) The pharmaceutical composition of claim 242, further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.

244. (New) The pharmaceutical composition of claim 243, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.

245. (New) A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 242.

246. (New) A pharmaceutical composition comprising:
- a) the polypeptide of claim 227; and
 - b) a pharmaceutically acceptable carrier.

247. (New) The pharmaceutical composition of claim 246, further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.

248. (New) The pharmaceutical composition of claim 247, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.

249. (New) A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 246.

250. (New) A pharmaceutical composition comprising:
- a) the polypeptide of claim 228; and
 - b) a pharmaceutically acceptable carrier.

251. (New) The pharmaceutical composition of claim 250, further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.

252. (New) The pharmaceutical composition of claim 251, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.

253. (New) A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 250.

254. (New) A pharmaceutical composition comprising:
a) the polypeptide of claim 229; and
b) a pharmaceutically acceptable carrier.

255. (New) The pharmaceutical composition of claim 254, further comprising an anticancer drug for the treatment of prostatic adenocarcinoma.

256. (New) The pharmaceutical composition of claim 255, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxotere, taxane, and mixtures thereof.

257. (New) A method of treating a patient having prostatic adenocarcinoma, the method comprising administering the pharmaceutical composition of claim 254.